-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, VtB9wlu99+8qUw9BbMIHChorgV7/Lo7AL9bxCL8FZa/hYHzu+IPXep7q8LG9b5JV MidfBiCeWGJWDrT8DcoUNA== 0000950142-10-000403.txt : 20100310 0000950142-10-000403.hdr.sgml : 20100310 20100310185050 ACCESSION NUMBER: 0000950142-10-000403 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20100308 FILED AS OF DATE: 20100310 DATE AS OF CHANGE: 20100310 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Soros Robert CENTRAL INDEX KEY: 0001387524 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33719 FILM NUMBER: 10671880 MAIL ADDRESS: STREET 1: C/O SOROS FUND MANAGEMENT LLC STREET 2: 888 SEVENTH AVENUE CITY: NEW YORK STATE: NY ZIP: 10106 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SOROS JONATHAN T ALLAN CENTRAL INDEX KEY: 0001387590 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33719 FILM NUMBER: 10671879 MAIL ADDRESS: STREET 1: C/O SOROS FUND MANAGEMENT LLC STREET 2: 888 SEVENTH AVENUE CITY: NEW YORK STATE: NY ZIP: 10106 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MAP Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001401923 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200507047 STATE OF INCORPORATION: DE BUSINESS ADDRESS: STREET 1: 2400 BAYSHORE PARKWAY, SUITE 200 CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 BUSINESS PHONE: 650-386-3100 MAIL ADDRESS: STREET 1: 2400 BAYSHORE PARKWAY, SUITE 200 CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SOROS GEORGE CENTRAL INDEX KEY: 0000900203 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33719 FILM NUMBER: 10671881 MAIL ADDRESS: STREET 1: 888 SEVENTH AVE STREET 2: 33RD FLR CITY: NEW YORK STATE: NY ZIP: 10106 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SOROS FUND MANAGEMENT LLC CENTRAL INDEX KEY: 0001029160 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33719 FILM NUMBER: 10671882 BUSINESS ADDRESS: STREET 1: 888 SEVENTH AVENUE STREET 2: 33RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10106 BUSINESS PHONE: (212) 872-1054 MAIL ADDRESS: STREET 1: 888 SEVENTH AVENUE STREET 2: 33RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10106 4 1 form4_sfmllc030810-mapex.xml FORM 4 X0303 4 2010-03-08 0 0001401923 MAP Pharmaceuticals, Inc. MAPP 0001029160 SOROS FUND MANAGEMENT LLC 888 SEVENTH AVENUE 31ST FLOOR NEW YORK NY 10106 0 0 1 0 0000900203 SOROS GEORGE 888 SEVENTH AVE 31ST FLR NEW YORK NY 10106 0 0 1 0 0001387524 Soros Robert C/O SOROS FUND MANAGEMENT LLC 888 SEVENTH AVENUE, 31ST FLOOR NEW YORK NY 10106 0 0 1 0 0001387590 SOROS JONATHAN T ALLAN C/O SOROS FUND MANAGEMENT LLC 888 SEVENTH AVENUE, 31ST FLOOR NEW YORK NY 10106 0 0 1 0 Common Stock 2010-03-08 4 S 0 3155 14.61 D 2843875 I See Footnote Common Stock 2010-03-08 4 S 0 81416 14.61 D 2843875 I See Footnote Common Stock 2010-03-09 4 S 0 634 15.40 D 2826875 I See Footnote Common Stock 2010-03-09 4 S 0 16366 15.40 D 2826875 I See Footnote The price shown in Column 4 is a weighted average sale price. The price range for the sales is $14.20 to $14.80. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. All of the securities reported herein are held for the account of Perseus-Soros BioPharmaceutical Fund, LP ("Perseus-Soros"), Perseus-Soros Partners, LLC ("Perseus-Soros Partners"), the general partner of Perseus-Soros, SFM Participation, L.P ("SFM Participation"), a managing member of Perseus-Soros Partners, as well as Biotech Management Partners, LLC ("Biotech Management Partners") and Quantum Industrial Partners, LDC ("QIP"). Perseus-Soros Partners is the general partner of Perseus-Soros. SFM Participation is a managing member of Biotech Management Partners and Perseus-Soros Partners. SFM AH, LLC, a Delaware limited liability company ("SFM AH"), is the general partner of SFM Participation. The sole managing member of SFM AH is SFM LLC. SFM LLC also serves as the principal investment manager to QIP. Mr. George Soros ("Mr. Soros") serves as Chairman of SFM LLC, Mr. Robert Soros ("Robert Soros") serves as Deputy Chairman of SFM LLC and Mr. Jonathan Soros ("Jonathan Soros") serves as President and Deputy Chairman of SFM LLC. Represents 3,155 shares of the Issuer's Common Stock sold by SFM Participation. After the sale, SFM Participation owns directly 634 shares of the Issuer's Common Stock. Represents 81,416 shares of the Issuer's Common Stock sold by QIP. After the sale QIP, owns directly 17,072 shares of the Issuer's Common Stock. The price shown in Column 4 is a weighted average sale price. The price range for the sales is $14.70 to $15.56 The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Represents 634 shares of the Issuer's Common Stock sold by SFM Participation. After the sale, SFM Participation owns directly no shares of the Issuer's Common Stock. Represents 16,366 shares of the Issuer's Common Stock sold by QIP. After the sale, QIP owns directly 706 shares of the Issuer's Common Stock. (9) Mr. Schoenfarber is signing in his capacity as Ass't General Counsel of Soros Fund Management LLC. (10) Mr. Schoenfarber is signing in his capacity as Attorney-in-Fact for Mr. George Soros. (11) Mr. Schoenfarber is signing in his capacity as Attorney-in-Fact for Mr. Robert Soros. (12) Mr. Schoenfarber is signing in his capacity as Attorney-in-Fact for Mr. Jonathan Soros. /s/ Jay Schoenfarber (9) 2010-03-10 /s/ Jay Schoenfarber (10) 2010-03-10 /s/ Jay Schoenfarber (11) 2010-03-10 /s/ Jay Schoenfarber (12) 2010-03-10 EX-99 2 ex99-1_sfmllc.htm EXHIBIT 99.1

Exhibit 99.1

 

Pursuant to Rule 16a-1(a)(2)(ii)(B) under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Soros, Robert Soros, Jonathan Soros and SFM LLC may be deemed to be beneficial owners of the shares beneficially owned by Perseus-Soros, Perseus-Soros Partners, SFM Participation, Biotech Management Partners, LLC and QIP only to the extent of the greater of his or its respective direct or indirect interest in the profits or capital account of each such entity. Pursuant to Rule 16a-1(a)(4) under the Act, this filing shall not be deemed an admission that Mr. Soros, Robert Soros, Jonathan Soros or SFM LLC, is for purposes of Section 16 of the Act or otherwise, the beneficial owner of any securities owned by Perseus-Soros, Perseus-Soros Partners, SFM Participation, Biotech Management Partners, LLC and QIP in excess of such amount.

 

 

 -----END PRIVACY-ENHANCED MESSAGE-----